Jiamin Cao

138 Tongzipo Road
Changsha, 410013, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence.

Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence.

Journal: Frontiers in immunology

Published: June 17, 2026

A bispecific-aptamer TSHR-CD80-1 treats thyroid eye disease by inhibiting CD8+ T cell-fibroblast interactions.

A bispecific-aptamer TSHR-CD80-1 treats thyroid eye disease by inhibiting CD8+ T cell-fibroblast interactions.

Journal: Cell communication and signaling : CCS

Published: February 03, 2026

Smoking-induced HLA-DQA1 overexpression in T cells: a novel pathway in thyroid eye disease development.

Smoking-induced HLA-DQA1 overexpression in T cells: a novel pathway in thyroid eye disease development.

Journal: Frontiers in immunology

Published: November 12, 2025

Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy.

Targeted Delivery of CD34 Aptamer-Coupled Tocilizumab Microspheres for Effective Treatment of Thyroid-Associated Ophthalmopathy.

Journal: Investigative ophthalmology & visual science

Published: August 25, 2025

Outcomes of Drainage Device Surgery in Uveitic Glaucoma: Systematic Review and Meta-Analysis.

Outcomes of Drainage Device Surgery in Uveitic Glaucoma: Systematic Review and Meta-Analysis.

Journal: Journal of glaucoma

Published: August 04, 2025

Role of cGAS-STING pathway in fibrotic disease.

Role of cGAS-STING pathway in fibrotic disease.

Journal: Pharmacological research

Published: July 28, 2025

The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease.

The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease.

Journal: Investigative ophthalmology & visual science

Published: July 14, 2025

GPX1-driven selenium nanoplatform reprograms MAMs-mediated organelle crosstalk to reverse inflammatory adipose expansion in thyroid eye disease.

GPX1-driven selenium nanoplatform reprograms MAMs-mediated organelle crosstalk to reverse inflammatory adipose expansion in thyroid eye disease.

Journal: Theranostics

Published: May 15, 2025

Quality and content evaluation of thyroid eye disease treatment information on TikTok and Bilibili.

Quality and content evaluation of thyroid eye disease treatment information on TikTok and Bilibili.

Journal: Scientific reports

Published: May 06, 2025

Biglycan knockdown improves Graves' orbitopathy (GO)-like features via inhibiting NF-kB and ERK signaling.

Biglycan knockdown improves Graves' orbitopathy (GO)-like features via inhibiting NF-kB and ERK signaling.

Journal: Journal of endocrinological investigation

Published: April 25, 2025

Triamcinolone Acetonide (TCA)-Loaded Biodegradable Microspheres Improve Therapeutic Outcomes in Thyroid-Associated Ophthalmopathy (TAO) by Reducing Fibrosis and Adipogenesis.

Triamcinolone Acetonide (TCA)-Loaded Biodegradable Microspheres Improve Therapeutic Outcomes in Thyroid-Associated Ophthalmopathy (TAO) by Reducing Fibrosis and Adipogenesis.

Journal: Journal of biomedical materials research. Part A

Published: March 05, 2025

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota.

Butyrate Ameliorates Graves' Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota.

Journal: Investigative ophthalmology & visual science

Published: March 04, 2025

Showing 1-12 of 33

Last Updated: 09/26/2026